Plasma hepcidin in early-stage breast cancer patients: No relationship with interleukin-6, erythropoietin and erythroferrone

Chiara Maura Ciniselli, Maida De Bortoli, Elena Taverna, Luca Varinelli, Sara Pizzamiglio, Silvia Veneroni, Chiara Bonini, Rosaria Orlandi, Paolo Verderio, Italia Bongarzone

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

Original languageEnglish
Pages (from-to)695-701
Number of pages7
JournalExpert Review of Proteomics
Volume12
Issue number6
DOIs
Publication statusPublished - Nov 2 2015

Fingerprint

Hepcidins
Erythropoietin
Interleukin-6
Breast Neoplasms
Plasmas
Breast Diseases
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Immunoassay
Anemia
Tumors
Iron
Inflammation

Keywords

  • benign breast disease
  • BMP6
  • breast cancer
  • early diagnosis
  • erytroferrone
  • erytropoiesis
  • erytropoietin
  • hepcidin
  • IL-6
  • inflammation
  • iron metabolism

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Plasma hepcidin in early-stage breast cancer patients : No relationship with interleukin-6, erythropoietin and erythroferrone. / Ciniselli, Chiara Maura; De Bortoli, Maida; Taverna, Elena; Varinelli, Luca; Pizzamiglio, Sara; Veneroni, Silvia; Bonini, Chiara; Orlandi, Rosaria; Verderio, Paolo; Bongarzone, Italia.

In: Expert Review of Proteomics, Vol. 12, No. 6, 02.11.2015, p. 695-701.

Research output: Contribution to journalArticle

@article{1372c10280944239ba35531ad78d8c8a,
title = "Plasma hepcidin in early-stage breast cancer patients: No relationship with interleukin-6, erythropoietin and erythroferrone",
abstract = "Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87{\%}) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.",
keywords = "benign breast disease, BMP6, breast cancer, early diagnosis, erytroferrone, erytropoiesis, erytropoietin, hepcidin, IL-6, inflammation, iron metabolism",
author = "Ciniselli, {Chiara Maura} and {De Bortoli}, Maida and Elena Taverna and Luca Varinelli and Sara Pizzamiglio and Silvia Veneroni and Chiara Bonini and Rosaria Orlandi and Paolo Verderio and Italia Bongarzone",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/14789450.2015.1099436",
language = "English",
volume = "12",
pages = "695--701",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Plasma hepcidin in early-stage breast cancer patients

T2 - No relationship with interleukin-6, erythropoietin and erythroferrone

AU - Ciniselli, Chiara Maura

AU - De Bortoli, Maida

AU - Taverna, Elena

AU - Varinelli, Luca

AU - Pizzamiglio, Sara

AU - Veneroni, Silvia

AU - Bonini, Chiara

AU - Orlandi, Rosaria

AU - Verderio, Paolo

AU - Bongarzone, Italia

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

AB - Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

KW - benign breast disease

KW - BMP6

KW - breast cancer

KW - early diagnosis

KW - erytroferrone

KW - erytropoiesis

KW - erytropoietin

KW - hepcidin

KW - IL-6

KW - inflammation

KW - iron metabolism

UR - http://www.scopus.com/inward/record.url?scp=84947490233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947490233&partnerID=8YFLogxK

U2 - 10.1586/14789450.2015.1099436

DO - 10.1586/14789450.2015.1099436

M3 - Article

AN - SCOPUS:84947490233

VL - 12

SP - 695

EP - 701

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 6

ER -